An audio webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation ...

Stock analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Thursday, January 2nd. HC Wainwright analyst S.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) just reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of patients with atopic dermatitis [AD]. Being that ...

Corvus Pharmaceuticals' stock plummeted ~40% after Phase 1 data for soquelitinib in atopic dermatitis showed mixed results, raising concerns about its efficacy. Phase 1 data for soquelitinib in AD ...

Fintel reports that on January 2, 2025, HC Wainwright & Co. initiated coverage of Corvus Pharmaceuticals (NasdaqGM:CRVS) with ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has earned a consensus recommendation of “Buy” from the four ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...

H.C. Wainwright initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $11 price target Corvus is a clinical-stage ...

Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical compan Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Corvus Pharmaceuticals shares interim Phase 1 trial data showing promising results for soquelitinib in treating moderate to severe atopic dermatitis.